India · Delayed Price · Currency is INR Fredun Pharmaceuticals Earnings Call Transcripts
Fiscal Year 2026
-
Q3 and nine-month FY26 saw strong revenue and profit growth, with significant margin expansion. Legacy business grew 15–20% YoY, while New Age segments like pet care and mobility are scaling rapidly. No immediate funding needs are anticipated, and margins are expected to improve as new brands mature.
-
Strong Q2 and H1 FY26 results with double-digit revenue and profit growth, driven by expansion in pet care, nutraceuticals, and mobility. Strategic acquisitions and manufacturing expansion support long-term growth, with positive cash flow and robust guidance for the coming years.
-
Q1 FY 2026 saw revenue rise 52% and net profit 64% year-on-year, driven by strong branded generics and pet care growth. The company targets to double revenue and PAT in 3-4 years, with new age business expected to contribute over half of future revenue.